{"product_id":"teprotumumab-elisa-kit-bhe21400340","title":"Teprotumumab ELISA Kit","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eTeprotumumab ELISA Kit\u003c\/strong\u003e is an ELISA-based immunoassay designed for quantitative measurement of \u003cstrong\u003eTeprotumumab\u003c\/strong\u003e in research samples. It is commonly used to generate traceable concentration data for biomarker discovery, pathway studies, and comparative analyses across experimental conditions.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay format:\u003c\/strong\u003e Quantitative Colorimetric ELISA. The format defines how signal scales with analyte abundance and how results are interpreted across a standard curve.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorking range and sensitivity:\u003c\/strong\u003e dynamic range 62.5 ng\/mL - 4,000 ng\/mL. Use these values to plan dilutions and keep readouts within the linear portion of the calibration curve.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSample compatibility:\u003c\/strong\u003e Intended for Plasma, Serum matrices. As with most immunoassays, matrix composition can influence apparent signal and should be evaluated with dilution linearity and spike-recovery concepts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecovery reference:\u003c\/strong\u003e Typical recovery is reported as 80-120%. Recovery helps assess whether the sample matrix interferes with detection of spiked analyte.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003ePRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant human IGF1R antigen has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Teprotumumab in the sample competitively binds to the pre-coated protein with biotin-labeled Teprotumumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Teprotumumab bound in the initial step. The color development is stopped and the intensity of the color is measured.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eTeprotumumab is a human IgG1 monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) that is used in the therapy of Graves ophthalmopathy (thyroid eye disease). Graves disease is an autoimmune disease associated with autoantibodies, hyperthyroidism and a distinctive form of eye disease marked by ocular inflammation and proptosis causing eye pain, dryness, redness, and swelling which if severe can cause diplopia (double-vision) and loss of vision. Graves ophthalmopathy is associated with autoantibodies to thyrotropin and hypertrophy of ocular fibroblasts which overexpress the IGF1 receptor. Teprotumumab causes inhibition of IGF1 binding to its receptor and preventing cell activation. IGF1 is a potent modulator of cell growth and inhibitor of programmed cell death, acting via the PI3K-AKT-mTOR pathway. The inhibition of IGF1 signaling decreases fibroblast proliferation and hypertrophy.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiomarker translation in RUO settings:\u003c\/strong\u003e Increasing use of quantitative immunoassays to stratify experimental cohorts, track longitudinal changes, and benchmark model systems.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix-aware assay design:\u003c\/strong\u003e Greater emphasis on dilution linearity, spike-recovery, and control concepts to reduce matrix-driven artifacts in serum\/plasma and complex lysates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntegration with multi-omics:\u003c\/strong\u003e ELISA measurements are often used alongside transcriptomics and proteomics to connect abundance changes with pathway activity and phenotype.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComparative quantification:\u003c\/strong\u003e Measure relative changes in analyte levels across treatments, time points, or genotypes to support mechanistic hypotheses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay development and standardization:\u003c\/strong\u003e Generate reproducible concentration inputs for method qualification, inter-operator comparisons, or bridging studies across platforms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eModel and sample characterization:\u003c\/strong\u003e Profile baseline and stimulated levels to help interpret immune, endocrine, neurodegenerative, or metabolic phenotypes (as relevant to the target).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically focuses on direction and magnitude of change in the context of controls and sample handling metadata, rather than single-point absolute values.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Hemolysis, lipemia, and high protein content can alter background and apparent concentration. Consider consistent collection\/processing and evaluate dilution behavior.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsoforms and modified forms:\u003c\/strong\u003e Some targets exist as isoforms, fragments, or post-translationally modified species. Ensure the measured form aligns with the biological question and the kit’s intended analyte definition.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e Use negative\/blank controls, replicate wells, and—when feasible—orthogonal confirmation (e.g., WB or MS) to strengthen conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProt (search): https:\/\/www.uniprot.org\/uniprotkb?query=Teprotumumab - NCBI Gene (search): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=Teprotumumab - Ensembl (search): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=Teprotumumab - PubMed (search): https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Teprotumumab - NCBI Bookshelf (background reviews): https:\/\/www.ncbi.nlm.nih.gov\/books\/?term=Teprotumumab --\u003e","brand":"Biohippo Inc","offers":[{"title":"96 T","offer_id":53047355146605,"sku":"DY353058-96T","price":1126.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/ELISA_Kits_Display_Image_1_03771ba2-47d4-4fef-a14a-71d32131dead.png?v=1772020770","url":"https:\/\/www.ebiohippo.com\/products\/teprotumumab-elisa-kit-bhe21400340","provider":"BioHippo","version":"1.0","type":"link"}